I CONGRESO DIGITAL AEP. Libro de comunicaciones y casos clínicos

807 ISBN: 978-84-09-24491-1 ÁREA DE ESPECIALIDAD • NEUROLOGÍA ASOCIACIÓN ESPAÑOLA DE PEDIATRÍA ESTUDIO. Are children and adolescents under antiepileptic therapy at risk of vitamin D deficiency? Mafalda Ferreira Santos, Jéssica França Sousa, Joana Correia Campos, Dora Gomes, Nuno Stattmiller Andrade Centro Hospitalar Tondela-Viseu, Viseu, Portugal INTRODUCCIÓN Y OBJETIVOS Vitamin D status was evaluated in a pediatric popula- tion under antiepileptic therapy (AET) to determine the prevalence and risk factors of vitaminDdeficiency. MÉTODOS A prospective and descriptive study was conducted. Data were collected frommedical records of pediatric patients followed in a Pediatric-Epilepsy consultation of a secundary Hospital from January of 2018 up to December of 2019. The study included pediatric pa- tients diagnosed with epilepsy and under AET last- ing for more than one year. Exclusion criteria were defined as ongoing therapy with vitamin D or on the previous 6 months. To carry out this project, the routine analytical study included - in an opportunistic way - the meas- urement of serum concentrations of 25-hydroxyvi- tamin D (25(OH)D3 in two separated moments 4 to 6 months apart. Potential risk factors for vitamin-D deficiency were assessed by age, gender, body mass index (BMI) percentile, seizure type, age at initiation of AET, type of AET instituted, monotherapy regimen or polytherapy and brain magnetic resonance imag- ing (MRI) findings. Vitamin-D deficiency was defined as 25(OH)D3 under 20 ng/ml, while insufficiency was defined as 25(OH)D3 between 21 and 29 ng/ml. The statistical analysis was performed using SPSS 20® program. RESULTADOS Medical records of 41 patients with ages between 7 and 17 years (mean age 12,44 ± 3,49 years) with 53.66%of themale gender, were analyzed. Themean baseline 25(OH)D3 level has decreased from 19.52 ± 6.91 to 17.61 ± 7.33 ng/ml and themean change in the 25(OH)D3 levels was -1.8 ng/ml. The rate of vitamin D deficiency was 53.66% (n = 22) and insufficiency was 34.15% (n = 14) on the first assessment with a similar rate on the second one. Only five patients had a vitamin D value above 30 ng/ml. Patients under polytherapy (17.22 ± 7.6 ng/ml), with therapy duration over 5 years (19.58 ± 9.1 ng/ml) and overweight/obese patients with BMI of eighty- fifth percentile or greater (16.67 ± 12.1 ng/ml) had a significant lower level of 25(OH)D3 ( p <0.01). Note- worthy, patients under therapy with carbamanzepine (enzyme-inducing antiepileptic drug) had lower lev- els of 25(OH)D3 (16.96 ± 7.9 ng/ml) versus patients on nonenzyme-inducing antiepileptic drugs (20.94 ± 9.1 ng/ml) ( p <0.03). CONCLUSIONES Serum levels of vitamin D were particularly low in almost all epileptic patients. This study emphasizes theneedof regularmonitor- ing of vitamin D levels during the treatment of child- hoodepilepsy. That isespeciallyrelevant inoverweight/ obese patients or when long-term AET or polytherapy are used, in order to prevent D-hypovitaminosis and impaired bone health in epileptic children.